|Cancer Stem Cell News 5.42 October 26, 2016|
The authors report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of myeloproliferative neoplasm through profound detrimental effects on hematopoietic stem cells. [Nature]
Researchers evaluated the therapeutic potential of natural killer (NK) cell-based adoptive immunotherapy against chemoresistant bladder cancer stem-like cells in a pre-clinical relevant model, using NK cells from healthy donors and non-muscle invasive bladder cancer patients. [BMC Med]
K5ΔNβcat transgenic mice present amplification of the basal stem cell pool and develop triple-negative mammary carcinomas. The loss of p53 in K5ΔNβcat mice led to an early expansion of mammary stem/progenitor cells and accelerated the formation of triple-negative tumors. [Oncogene]
Scientists showed enrichment of CD133 in Group 3 medulloblastoma (MB) is associated with increased rate of metastasis and poor clinical outcome. The signal transducers and activators of transcription-3 (STAT3) pathway are selectively activated in CD133+ MB stem cells and promote tumorigenesis through regulation of c-MYC, a key genetic driver of Group 3 MB. [Oncogene]
Researchers’ results demonstrate that HULC, MALAT1 and TRF2 are highly expressed in human hepatocellular carcinoma tissues, and HULC plus MALAT1 overexpression drastically promotes the growth of liver cancer stem cells. [Sci Rep]
The authors report the cancer stem cell (CSC) potency of a novel series of copper(ii)-phenanthroline complexes bearing nonsteriodial anti-inflammatory drugs: naproxen, tolfenamic acid, and indomethacin (2a-3c). Two of the complexes, 2a and 3c, kill breast CSC-enriched HMLER-shEcad cells to a significantly better extent than salinomycin, a well-established CSC toxin. [Dalton Trans]
Scientists found that isolation of spheroid body cells from MKN-45 and AGS cells without using growth factors is an easy and inexpensive method to isolate cancer stem cells and knockdown of placental growth factor (PlGF) in spheroid body cells reduced in vitro tumorigenicity and stemness properties of spheroid body cells such as self-renewal ability, colony forming, migratory, and MMPs activities and decreased ability to differentiation and angiogenesis. [J Cell Biochem]
Investigators examined interstitial fluid flow-stimulated CXCR4-, CXCL12-, and CD44-dependent invasion in patient-derived glioblastoma stem cells (GSCs). Using their 3D in vitro assay and correlative in vivo studies they demonstrated GSC lines show increased invasion with flow. This flow-stimulated invasion was reduced by blockade of CXCR4, CXCL12, and/or CD44, revealing that GSC invasion may be mediated simultaneously by both mechanisms. [Integr Biol (Camb)]
Investigators evaluated the anticancer efficacy of a novel derivative of matrine, (6aS, 10S, 11aR, 11bR, 11cS)-10- methylamino-dodecahydro- 3a,7a-diaza-benzo (de), against human hepatocellular carcinoma cells and their corresponding sphere cells in vitro and in vivo. [Acta Pharmacol Sin]
Investigators identified the putative origin cells of breast cancer subtype stem cells (BCSSCs) through comparing gene signatures between BCSSCs and normal mammary cells from multiple perspectives: common signature, expression consistency, functional similarity and shortest path length. [PLoS One]
The authors attempt to summarize recent studies of glioblastoma-associated deubiquitinating enzymes (DUBs), their roles in various cellular processes, and discuss the relation between DUBs deregulation and gliomagenesis, especially how DUBs regulate glioma stem cells pluripotency, microenvironment, and resistance of radiation and chemotherapy through core stem-cell transcriptional factors. [Med Res Rev]
By understanding the impact of epigenetic control on the tumor microenvironment, rational combinatorial epigenetic and checkpoint blockage therapies have potential to harness the immune system for the treatment of cancer. [J Pathol]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Boston Biomedical announced dosing of the first patient in CanStem303C, a new global Phase III study investigating napabucasin in combination with standard of care in patients with previously treated metastatic colorectal carcinoma. [Boston Biomedical]
Bristol-Myers Squibb Company announced new results from CheckMate-205, a multi-cohort, single-arm, Phase II trial evaluating Opdivo in patients with classical Hodgkin lymphoma. [Bristol-Myers Squibb Company]
Emulate, Inc. announced its strategic collaboration with the Lawrence J. Ellison Institute for Transformative Medicine of University of Southern California (USC) to use Emulate’s Organs-on-Chips technology to conduct leading-edge translational R&D that can advance cancer treatment and patient well-being. [Emulate, Inc.]
Many in Canada’s science community say they are reserving judgement, waiting to see whether Trudeau can sustain his string of victories as he tackles some of country’s thorniest science-policy issues. [Nature News]
For the first time in its 68-year history, the World Health Organization (WHO) has concluded that researchers are guilty of research misconduct. An independent review commissioned by WHO has found that “research ethics misconduct occurred” in a multimillion-dollar global study on fetal growth led by researchers at the University of Oxford in the United Kingdom. [ScienceInsider]
One of the biggest nonprofit biomedical research outfits in the world is getting a new translational medicine research arm, aimed at speeding the conversion of basic research insights into novel medicines. Officials at the Scripps Research Institute announced that it will merge with the California Institute for Biomedical Research, which was launched in 2012 as a nonprofit version of a drug development company. [ScienceInsider]
The National Science Foundation (NSF) has decided that universities should pay 10% of the salaries of faculty members working temporarily at the agency. NSF hopes the new policy will demonstrate its commitment to saving taxpayer dollars without alienating the academic community that it relies upon to stay on the cutting edge of basic science. [ScienceInsider]
NEW EMBL-Cancer Core Europe Conference: Cancer Immunotherapy
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.
Home Cancer Stem Cell News Volume 5.42 | Oct 26 2016